WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
CALGARY, AB, Oct. 10, 2023 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering of convertible debenture units of the Company (the “Debenture Units“), on a non-brokered private placement basis, for aggregate proceeds of C$800,000 (the “Offering“). The Offering was led by insiders including members of the Board of Directors and members of the senior management team of the Company, who subscribed for a total of C$515,000.
Related news for (CANSF)
- WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
- WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY
- WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
- WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM